2020
A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status.
Modlin I, Kidd M, Kitz A, Drozdov I, Malczewska A, Kusnierz K, Aslanian H. A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status. Journal Of Clinical Oncology 2020, 38: e16079-e16079. DOI: 10.1200/jco.2020.38.15_suppl.e16079.Peer-Reviewed Original ResearchStable diseaseColorectal cancerProgressive diseaseCA 19Cancer liquid biopsyLiquid biopsySurgical resection samplesBlood-based biomarkersCell linesResection samplesSurgical cohortSurgical resectionChemotherapy patientsCRC tumorsScore utilityClinical utilityBlood samplesColon cancerAUROC analysisDisease statusTumor tissueDiagnostic accuracyGene expressionCohortFunctional enrichment analysisA 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status.
Modlin I, Kidd M, Drozdov I, Kitz A, Malczewska A, Kusnierz K, Aslanian H. A 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status. Journal Of Clinical Oncology 2020, 38: 18-18. DOI: 10.1200/jco.2020.38.4_suppl.18.Peer-Reviewed Original ResearchColorectal cancerStable diseaseProgressive diseaseClinical utilityCA 19CRC tumorsCancer liquid biopsyLiquid biopsyBlood-based biomarkersSurgical resectionChemotherapy patientsDisease burdenScore utilityBlood signatureBlood samplesAUROC analysisDisease statusDiagnostic accuracyGene expressionDiseaseCandidate markersResectionExpression levelsBiopsyCEA
2015
The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract
Modlin I, Kidd M, Bodei L, Drozdov I, Aslanian H. The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract. The American Journal Of Gastroenterology 2015, 110: 1223. PMID: 26032155, DOI: 10.1038/ajg.2015.160.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsCgA measurementMalignant gastrointestinal diseasesBlood-based biomarkersNeuroendocrine tumor diseaseExtensive diseaseIntestinal carcinoidsColorectal cancerGastrointestinal diseasesCgA levelsPancreatic diseaseClinical utilityGastrointestinal tractDiagnostic strategiesNETestDiseaseTumorsNETest scoreTumor diseaseNovel bloodNational InstituteDiagnosisBiomarkersCgA
1998
Altered MLH1 and MSH2 expression in colorectal cancer is associated with proximal site but not risk of metachronicity: Results of a case-control study
Aslanian H, Ahlquist D, Burgart L, Roche P, Harrington J, Mahoney D, Zinsmeister A, Thibodeau S, Group C. Altered MLH1 and MSH2 expression in colorectal cancer is associated with proximal site but not risk of metachronicity: Results of a case-control study. Gastroenterology 1998, 114: a559. DOI: 10.1016/s0016-5085(98)82275-0.Peer-Reviewed Original Research